US5120713A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
Assignee: Merck Serono SA
•
Filing: 1990-09-10
•
Granted: 1992-06-09
•
Expires: 2010-09-10
Abstract
Abstract Obese patients may be effectively treated by cojointly administering an alpha-2-adrenergic agonist, such as clonidine, and a growth hormone releasing peptide, such as GHRH, to restore or substantially enhance growth hormone release in such patients.
Inventors
- 👤 Jesus D. Mugica
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 02:47
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/25; A61P; A61P25/00; A61P25/02; A61P3/00; A61P3/04
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
31 words
A method of inducing growth hormone secretion in an obese patient which comprises administering cojointly to said patient an effective amount of an alpha-2-adrenergic agonist and a growth hormone releasing peptide.
Claim 2
Independent Claim
31 words
A method of inducing growth hormone secretion in an obese patient which comprises administering cojointly to said patient an effective amount of an alpha-2-adrenergic agonist and a growth hormone releasing peptide.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein said alpha-2-adrenergic agonist is clonidine.
Claim 4
Dependent Claim
23 words
The method of claim 2 wherein said clonidine is administered from 0 to about 120 minutes prior to said growth hormone releasing peptide.
Claim 5
Dependent Claim
21 words
The method of claim 3 wherein said growth hormone releasing peptide is GRF 1-44, GRF 1-40, GRF 1-37, or GRF 1-29.
Claim 6
Dependent Claim
22 words
The method of claim 2 wherein said clonidine is administered in an amount of about 100 to about 300 micrograms/m 2 .
Claim 7
Dependent Claim
26 words
The method of claim 4 wherein said growth hormone releasing peptide is administered in an amount of about 1 ug/kg i.v. or about 10 ug/kg s.c..
Claim 8
Dependent Claim
19 words
The method of claim 4 wherein said clonidine is administered in an amount of about 150 micrograms/m 2 .
Claim 9
Dependent Claim
34 words
The method of claim 1 wherein said growth hormone releasing peptide has the formula AA 1 -His-AA 3 -Ala-Trp-D-Phe-Lys-NH 2 wherein AA 1 is H or Ala and AA 3 is D-Trp or D-β-Nal.
Claim 10
Independent Claim
36 words
A method of treating obesity which comprises administering to a patient with this condition an alpha-2-adrenergic agonist cojointly with a growth hormone releasing peptide in an amount effective to induce growth hormone secretion in said patient.
Claim 11
Independent Claim
36 words
A method of treating obesity which comprises administering to a patient with this condition an alpha-2-adrenergic agonist cojointly with a growth hormone releasing peptide in an amount effective to induce growth hormone secretion in said patient.
Claim 12
Dependent Claim
11 words
The method of claim 9 wherein said alpha-2-adrenergic agonist is clonidine.
Claim 13
Dependent Claim
23 words
The method of claim 10 wherein said clonidine is administered from 0 to about 120 minutes prior to said growth hormone releasing peptide.
Claim 14
Dependent Claim
21 words
The method of claim 11 wherein said growth hormone releasing peptide is GRF 1-44, GRF 1-40, GRF 1-37, or GRF 1-29.
Claim 15
Dependent Claim
22 words
The method of claim 10 wherein said clonidine is administered in an amount of about 100 to about 300 micrograms/m 2 .
Claim 16
Dependent Claim
26 words
The method of claim 12 wherein said growth hormone releasing peptide is administered in an amount of about 1 ug/kg i.v. or about 10 ug/kg s.c..
Claim 17
Dependent Claim
19 words
The method of claim 12 wherein said clonidine is administered in an amount of about 150 micrograms/m 2 .
Claim 18
Dependent Claim
15 words
The method of claim 9 which additionally comprises placing said patient on a hypocaloric diet.
Claim 19
Dependent Claim
34 words
The method of claim 9 wherein said growth hormone releasing peptide has the formula AA 1 -His-AA 3 -Ala-Trp-D-Phe-Lys-NH 2 wherein AA 1 is H or Ala and AA 3 is D-Trp or D-β-Nal.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-09 | 1995-12-09 | 1996-06-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-09 | 1999-12-09 | 2000-06-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-09 | 2003-12-09 | 2004-06-09 | $7700.00 | Window Closed / Lapsed |